Investors are poised to add Mineralys Therapeutics Inc (MLYS) Stock to their long term portfolios

At the time of writing, Mineralys Therapeutics Inc [MLYS] stock is trading at $12.34, up 4.31%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MLYS shares have gain 3.70% over the last week, with a monthly amount drifted -2.06%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on July 10, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, Goldman started tracking the stock with Buy rating on April 02, 2024, and set its price target to $30. On March 07, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $45 on March 07, 2023. Guggenheim initiated its recommendation with a Buy and recommended $32 as its price target on March 07, 2023. In a note dated March 07, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $40 on this stock.

For the past year, the stock price of Mineralys Therapeutics Inc fluctuated between $7.29 and $16.91. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $12.34 at the most recent close of the market. An investor can expect a potential return of 143.11% based on the average MLYS price forecast.

Analyzing the MLYS fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.56 and Total Capital is -0.71.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.76 points at the first support level, and at 11.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.71, and for the 2nd resistance point, it is at 13.08.

Ratios To Look Out For

It is important to note that Mineralys Therapeutics Inc [NASDAQ:MLYS] has a current ratio of 8.55. Further, the Quick Ratio stands at 8.55, while the Cash Ratio is 3.11.

Transactions by insiders

Recent insider trading involved Rodman David Malcom, Chief Medical Officer, that happened on Nov 11 ’24 when 5026.0 shares were sold. Officer, Rodman David Malcom completed a deal on Nov 11 ’24 to buy 5026.0 shares. Meanwhile, Chief Medical Officer Rodman David Malcom sold 25482.0 shares on Nov 06 ’24.

Related Posts